Atossa Therapeutics (ATOS) Short Interest Ratio & Short Volume $0.96 -0.02 (-1.66%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Atossa Therapeutics Short Interest DataAtossa Therapeutics (ATOS) has a short interest of 11.60 million shares. This marks a -6.83% decrease in short interest from the previous month. The short interest ratio (days to cover) is 18.5, indicating that it would take 18.5 days of the average trading volume of 1.06 million shares to cover all short positions.Current Short Interest11,600,000 sharesPrevious Short Interest12,450,000 sharesChange Vs. Previous Month-6.83%Dollar Volume Sold Short$15.08 millionShort Interest Ratio18.5 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares125,801,000 sharesPercentage of Shares Shorted9.22%Today's Trading Volume1,086,210 sharesAverage Trading Volume1,064,680 sharesToday's Volume Vs. Average102% Short Selling Atossa Therapeutics? Sign up to receive the latest short interest report for Atossa Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATOS Short Interest Over TimeATOS Days to Cover Over TimeATOS Percentage of Float Shorted Over Time Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Atossa Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202411,600,000 shares $15.08 million -6.8%N/A18.5 $1.30 11/15/202412,450,000 shares $15.94 million -2.5%N/A20.5 $1.28 10/31/202412,770,000 shares $17.62 million -2.2%N/A24.4 $1.38 10/15/202413,050,000 shares $18.66 million +0.9%N/A24.1 $1.43 9/30/202412,930,000 shares $19.65 million -1.9%N/A20 $1.52 9/15/202413,180,000 shares $20.03 million +2.2%N/A13.2 $1.52 Get the Latest News and Ratings for ATOS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202412,900,000 shares $17.67 million +0.3%N/A12.8 $1.37 8/15/202412,860,000 shares $16.46 million +1.1%N/A12 $1.28 7/31/202412,720,000 shares $17.17 million +3.1%N/A10.4 $1.35 7/15/202412,340,000 shares $17.28 million +20.0%N/A9.3 $1.40 6/30/202410,280,000 shares $12.23 million -5.6%N/A6.8 $1.19 6/15/202410,890,000 shares $13.07 million -2.9%N/A6.4 $1.20 5/31/202411,220,000 shares $14.59 million -2.3%N/A5.9 $1.30 5/15/202411,480,000 shares $18.48 million +0.4%N/A6 $1.61 4/30/202411,440,000 shares $17.27 million -7.4%N/A6.4 $1.51 4/15/202412,350,000 shares $21.12 million +17.0%N/A7.6 $1.71 3/31/202410,560,000 shares $19.01 million +24.5%N/A7.7 $1.80 3/15/20248,480,000 shares $10.94 million +18.6%N/A9 $1.29 2/29/20247,150,000 shares $6.99 million +1.6%N/A13.6 $0.98 2/15/20247,040,000 shares $7.11 million +2.9%N/A16.8 $1.01 1/31/20246,840,000 shares $5.84 million -2.2%N/A17.4 $0.85 1/15/20246,990,000 shares $6.36 million +9.9%N/A18.4 $0.91 12/31/20236,360,000 shares $5.60 million +1.0%N/A16.7 $0.88 12/15/20236,300,000 shares $4.67 million +1.0%N/A19.3 $0.74 11/30/20236,240,000 shares $4.64 million -2.0%N/A19.3 $0.74 11/15/20236,370,000 shares $4.17 million -4.2%N/A17.4 $0.65 10/31/20236,650,000 shares $4.46 million -5.7%N/A16.4 $0.67 10/15/20237,050,000 shares $4.65 million -2.8%N/A16.3 $0.66 9/30/20237,250,000 shares $5.34 million -8.8%N/A13.1 $0.74 9/15/20237,950,000 shares $6.28 million -3.1%N/A9.7 $0.79 8/31/20238,200,000 shares $6.48 million -1.8%N/A9.6 $0.79 8/15/20238,350,000 shares $7.36 million -1.7%N/A8.6 $0.88 7/31/20238,490,000 shares $9.34 million -2.6%N/A9.1 $1.10 7/15/20238,720,000 shares $10.81 million +12.5%N/A9.5 $1.24 6/30/20237,750,000 shares $9.77 million +6.9%N/A9.8 $1.26 6/15/20237,250,000 shares $6.52 million -3.6%N/A14.4 $0.90 5/31/20237,520,000 shares $6.99 million -3.2%N/A16.1 $0.93 5/15/20237,770,000 shares $5.50 million -3.7%N/A22.4 $0.71 4/30/20238,070,000 shares $5.16 million -3.1%N/A24.9 $0.64 4/15/20238,330,000 shares $6.12 million -1.3%N/A24.4 $0.74Cackling Kamala hates this company (Ad)Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. 3/31/20238,440,000 shares $6.12 million -1.9%N/A19.4 $0.72 3/15/20238,600,000 shares $5.59 million +0.6%N/A17.1 $0.65 2/28/20238,550,000 shares $6.33 million -2.2%N/A15.5 $0.74 2/15/20238,740,000 shares $6.69 million -0.6%N/A15.9 $0.77 1/31/20238,790,000 shares $7.04 million -3.2%N/A15.6 $0.80 1/15/20239,080,000 shares $7.75 million -1.7%N/A15.5 $0.85 12/30/20229,240,000 shares $4.88 million -3.7%N/A18.1 $0.53 12/15/20229,590,000 shares $5.61 million -4.3%N/A21.2 $0.59 11/30/202210,020,000 shares $7.52 million -4.1%N/A22.4 $0.75 11/15/202210,450,000 shares $8.58 million -0.2%N/A23.7 $0.82 10/31/202210,470,000 shares $10.32 million -1.2%N/A19.5 $0.99 10/15/202210,600,000 shares $8.59 million -5.8%N/A19.2 $0.81 9/30/202211,250,000 shares $9.37 million -1.6%N/A18.9 $0.83 9/15/202211,430,000 shares $10.53 million -2.8%N/A11.8 $0.92 8/31/202211,760,000 shares $10.83 million -1.3%N/A10.1 $0.92 8/15/202211,910,000 shares $13.58 million -3.7%N/A9 $1.14 7/31/202212,370,000 shares $11.64 million -1.9%N/A8.9 $0.94 7/15/202212,610,000 shares $12.99 million -3.7%N/A7.9 $1.03 6/30/202213,100,000 shares $14.28 million -18.3%N/A7.5 $1.09 6/15/202216,040,000 shares $16.68 million -1.3%N/A8.7 $1.04 5/31/202216,250,000 shares $15.80 million -5.2%N/A9.4 $0.97 5/15/202217,140,000 shares $16.90 million -11.4%N/A9.4 $0.99 4/30/202219,350,000 shares $19.54 million +8.9%N/A9.6 $1.01 4/15/202217,770,000 shares $19.72 million +1.7%N/A8.7 $1.11 3/31/202217,480,000 shares $21.85 million -2.7%N/A8.4 $1.25 3/15/202217,960,000 shares $21.19 million +7.4%N/A7.5 $1.18 2/28/202216,720,000 shares $20.40 million -1.1%N/A6.6 $1.22 2/15/202216,910,000 shares $23.34 million +2.3%N/A6.4 $1.38 1/31/202216,530,000 shares $22.65 million -3.7%14.1%5.7 $1.37 1/15/202217,160,000 shares $25.05 million -0.8%N/A5.7 $1.46 12/31/202117,290,000 shares $27.66 million -3.8%N/A5.3 $1.60 12/15/202117,980,000 shares $35.42 million No ChangeN/A5.3 $1.97 11/30/202117,980,000 shares $40.81 million -3.1%N/A4.6 $2.27 11/15/202118,550,000 shares $47.67 million -3.3%N/A4 $2.57 10/29/202119,190,000 shares $49.32 million -8.5%N/A3.9 $2.57 10/15/202120,970,000 shares $59.97 million -5.9%N/A3.3 $2.86 9/30/202122,280,000 shares $72.63 million -5.9%N/A2.4 $3.26 9/15/202123,670,000 shares $78.82 million -3.8%N/A1.7 $3.33 8/31/202124,600,000 shares $93.48 million +3.9%N/A1.5 $3.80 8/13/202123,670,000 shares $76.22 million -24.3%N/A1.2 $3.22 7/30/202131,280,000 shares $93.53 million +21.6%N/A1.5 $2.99 7/15/202125,730,000 shares $144.60 million +25.3%21.3%1.2 $5.62 6/30/202120,530,000 shares $129.75 million +24.3%17.0%1.1 $6.32 6/15/202116,520,000 shares $76.32 million +20.0%13.7%1.1 $4.62 5/28/202113,770,000 shares $44.34 million +2.9%11.4%1 $3.22 5/14/202113,380,000 shares $31.58 million +0.7%N/A1.2 $2.36 4/30/202113,290,000 shares $30.83 million +26.7%N/A1.1 $2.32 4/15/202110,490,000 shares $19.51 million +4.5%N/A0.5 $1.86 3/31/202110,040,000 shares $20.58 million +52.4%N/A0.4 $2.05 3/15/20216,590,000 shares $19.18 million -6.7%N/A0.3 $2.91Cackling Kamala hates this company (Ad)Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. 2/26/20217,060,000 shares $20.54 million +22.6%N/A0.3 $2.91 2/12/20215,760,000 shares $18.37 million -37.4%N/A0.3 $3.19 1/29/20219,200,000 shares $19.14 million +9.0%N/A0.5 $2.08 1/15/20218,440,000 shares $10.55 million +1,172.4%N/A0.7 $1.25 12/31/2020663,300 shares $583,637.67 -76.3%N/A0.1 $0.88 12/15/20202,800,000 shares $2.53 million +529.6%N/A1.2 $0.90 11/30/2020444,700 shares $773,778.00 +53.1%N/A0.6 $1.74 11/15/2020290,400 shares $455,928.00 +45.1%N/A1.2 $1.57 10/30/2020200,100 shares $310,155.00 +15.9%N/A0.7 $1.55 10/15/2020172,700 shares $376,486.00 -15.2%N/A0.4 $2.18 9/30/2020203,600 shares $492,712.00 +53.7%N/A0.3 $2.42 9/15/2020132,500 shares $308,725.00 -35.0%N/A0.2 $2.33 8/31/2020203,700 shares $519,435.00 -20.3%N/A0.3 $2.55 8/14/2020255,500 shares $947,905.00 +43.4%N/A0.3 $3.71 7/31/2020178,200 shares $673,596.00 +5.4%N/A0.2 $3.78 7/15/2020169,100 shares $669,636.00 -12.8%N/A0.2 $3.96 6/30/2020193,800 shares $736,440.00 -17.6%N/A0.2 $3.80 6/15/2020235,300 shares $724,724.00 -23.1%N/A0.2 $3.08 5/29/2020306,000 shares $728,280.00 +46.9%N/A0.4 $2.38 5/15/2020208,300 shares $354,110.00 -18.7%N/A0.3 $1.70 4/30/2020256,300 shares $558,734.00 +7.1%2.8%0.5 $2.18 4/15/2020239,400 shares $366,282.00 -1.0%2.6%0.5 $1.53 3/31/2020241,800 shares $527,124.00 +6.4%2.7%1.1 $2.18 3/13/2020227,200 shares $336,256.00 +0.1%2.5%2.4 $1.48 2/28/2020226,900 shares $206,479.00 -2.1%2.5%2.8 $0.91 2/14/2020231,700 shares $243,285.00 -2.5%2.6%2.9 $1.05 1/31/2020237,600 shares $304,128.00 -28.2%2.6%2.7 $1.28 1/15/2020331,100 shares $463,540.00 -2.2%3.6%3.9 $1.40 12/31/2019338,500 shares $524,675.00 +1.5%3.7%3.2 $1.55 ATOS Short Interest - Frequently Asked Questions What is Atossa Therapeutics' current short interest? Short interest is the volume of Atossa Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 11,600,000 shares of ATOS short. Learn More on Atossa Therapeutics' current short interest. What is a good short interest ratio for Atossa Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATOS shares currently have a short interest ratio of 18.0. Learn More on Atossa Therapeutics's short interest ratio. Which institutional investors are shorting Atossa Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Atossa Therapeutics: Wolverine Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Atossa Therapeutics' short interest increasing or decreasing? Atossa Therapeutics saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 11,600,000 shares, a decrease of 6.8% from the previous total of 12,450,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Atossa Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atossa Therapeutics: PureTech Health plc (0.09%), Humacyte, Inc. (19.60%), AnaptysBio, Inc. (27.33%), CorMedix Inc. (11.36%), Mereo BioPharma Group plc (4.27%), Xeris Biopharma Holdings, Inc. (6.65%), ABIVAX Société Anonyme (0.88%), MeiraGTx Holdings plc (1.89%), Cartesian Therapeutics, Inc. (19.85%), Monte Rosa Therapeutics, Inc. (23.93%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Atossa Therapeutics stock? Short selling ATOS is an investing strategy that aims to generate trading profit from Atossa Therapeutics as its price is falling. ATOS shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atossa Therapeutics? A short squeeze for Atossa Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATOS, which in turn drives the price of the stock up even further. How often is Atossa Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATOS, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies PureTech Health Short Interest Humacyte Short Interest AnaptysBio Short Interest CorMedix Short Interest Mereo BioPharma Group Short Interest Xeris Biopharma Short Interest ABIVAX Société Anonyme Short Interest MeiraGTx Short Interest Cartesian Therapeutics Short Interest Monte Rosa Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATOS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
